Denis M, Math xe9 D, Micoud M, Choffour P, Grasselly C, Matera E, et al. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. Front Immunol. 2022;13:1011943 pubmed publisher

Lau P, Zhang G, Zhao S, Liang L, Zhang H, Zhou G, et al. Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. Cell Mol Immunol. 2022;19:1153-1167 pubmed publisher

Reticker Flynn N, Zhang W, Belk J, Basto P, Escalante N, Pilarowski G, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185:1924-1942.e23 pubmed publisher

Burger M, Cruz A, Crossland G, Gaglia G, Ritch C, Blatt S, et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell. 2021;184:4996-5014.e26 pubmed publisher

Di Pilato M, Kfuri Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;: pubmed publisher

Pingili A, Chaib M, Sipe L, Miller E, Teng B, Sharma R, et al. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep. 2021;35:109285 pubmed publisher

Mitchell J, Lund M, Starmer J, Ge K, Magnuson T, Shpargel K, et al. UTX promotes CD8+ T cell-mediated antiviral defenses but reduces T cell durability. Cell Rep. 2021;35:108966 pubmed publisher

Starkl P, Watzenboeck M, Popov L, Zahalka S, Hladik A, Lakovits K, et al. IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against Staphylococcusaureus. Immunity. 2020;53:793-804.e9 pubmed publisher

Sheikh A, Cooper L, Feng M, Souza Fonseca Guimaraes F, Lafouresse F, Duckworth B, et al. Context-Dependent Role for T-bet in T Follicular Helper Differentiation and Germinal Center Function following Viral Infection. Cell Rep. 2019;28:1758-1772.e4 pubmed publisher

Chow M, Ozga A, Servis R, Frederick D, Lo J, Fisher D, et al. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity. 2019;: pubmed publisher